If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 13

A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors

Objective
The purpose of this study is to learn more about an investigational drug called DS-3939a. DS-3939a is an investigational drug that is not approved for your disease. It is being studied to see if it is safe and if your disease or medical condition improves while taking it.
Protocol No
DAIICHI-SANKYO-DS3939-077
Categories
Cancer, Prostate and Urologic Cancers, Kidney, Skin Cancers, Stomach, Uterine, Head and Neck Cancers, Esophagus, Thoracic Cancers, Ovary, Other Gastrointestinal, Sarcoma, Gastrointestinal Cancers, Prostate, Cervix, Gynecologic Cancers, Early Phase/Multiple Disease Site Cancers, Breast Cancers

REMASTer: REcurrent Brain Metastases After SRS Trial

Objective
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Protocol No
MONTERIS-CL10153-REMASTER
Categories
Cancer, Endocrine Cancers, Uterine, Other Urologic, Colorectal, Cervix, Lung, Brain and Spine Cancers, Prostate, Stomach, Skin Cancers, Prostate and Urologic Cancers, Other Respiratory, Gastrointestinal Cancers, Breast Cancers, Head and Neck Cancers, Esophagus, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Gynecologic Cancers, Sarcoma, Eye/Orbital Cancers

A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-Based Treatment Combinations or MK-5684 Alone in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Objective
Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Protocol No
MERCK-MK-5684-01A
Categories
Cancer, Prostate, Prostate and Urologic Cancers

A Phase 1, Open-Label, Multicenter, First-in-Human Trial of DS3610A in Participants With Advanced Solid Tumors

Objective
A Phase 1 Study of DS3610A in participants with advance solid tumor cancer.
Protocol No
DAIICHI-DS3610-071
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Lip, Oral Cavity and Pharynx, Other Skin, Other Respiratory, Colorectal, Pancreas/Liver, Skin Cancers, Other Gynecologic, Other Gastrointestinal, Ovary, Prostate, Thoracic Cancers, Gastrointestinal Cancers, Sarcoma, Uterine, Kidney, Gynecologic Cancers, Breast Cancers, Eye/Orbital Cancers, Head and Neck Cancers, Other Urologic, Endocrine Cancers, Prostate and Urologic Cancers